Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group AG    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations
Most relevant news about LONZA GROUP AG
11/19LONZA : and Be The Match BioTherapies partner to expand Vein-to-Vein Cell and Ge..
PU
11/19LONZA : Expands Highly Potent Drug Product Development and Manufacturing Capabil..
AQ
11/16LONZA : aims to make ingredients for 400 million doses of Moderna's COVID vaccin..
RE
11/16LONZA : aims to make ingredients for 400 mln doses of Moderna's COVID vaccine an..
RE
11/16LONZA : Congratulates Moderna on Interim Phase 3 Clinical Trial Data
PU
11/12LONZA : FUJIFILM Cellular Dynamics and Lonza Agree to Expand the Availability an..
PU
11/11PolyPeptide targets 2021 IPO or sale - sources
RE
11/11LONZA : Announces Broad Selection of High-Resolution HLA-typed Primary Cell Lots..
AQ
11/10LONZA : Altimmune Adds Lonza as a Manufacturing Partner for Supply of AdCOVID, i..
PU
11/09LONZA : and Ypsomed enter into a Collaboration for Development and Manufacturing..
PU
11/05LONZA : Celebrates the Grand Opening of a New Facility for ADC Payload Manufactu..
PU
11/03LONZA : Welcomes New Group Chief Executive Officer Pierre-Alain Ruffieux
AQ
11/02LONZA : Welcomes New Group Chief Executive Officer Pierre-Alain Ruffieux
PU
10/30Lonza to make COVID-19 antibody combination for AstraZeneca
RE
10/30LONZA : to make COVID-19 antibody combination for AstraZeneca
RE
More most relevant news
All news about LONZA GROUP AG
11/19LONZA : and Be The Match BioTherapies partner to expand Vein-to-Vein Cell and Ge..
PU
11/19LONZA : Expands Highly Potent Drug Product Development and Manufacturing Capabil..
AQ
11/17MODERNA : Lonza Congratulates Moderna on Interim Phase 3 Clinical Trial Data
AQ
11/16Breakthrough COVID vaccine tech could help defeat other diseases
RE
11/16LONZA : aims to make ingredients for 400 million doses of Moderna's COVID vaccin..
RE
11/16LONZA : aims to make ingredients for 400 mln doses of Moderna's COVID vaccine an..
RE
11/16LONZA : Congratulates Moderna on Interim Phase 3 Clinical Trial Data
PU
11/13FUJIFILM : Cellular Dynamics and Lonza Agree to Expand the Availability and Use ..
AQ
11/12LONZA : FUJIFILM Cellular Dynamics and Lonza Agree to Expand the Availability an..
PU
11/11PolyPeptide targets 2021 IPO or sale - sources
RE
More news
News in other languages on LONZA GROUP AG
11/25Hersteller Moderna will Corona-Impfstoff schon im Dezember liefern
11/19Lonza collabore avec la firme américaine Be The Match BioTherapies
11/19Lonza geht Partnerschaft mit Be The Match BioTherapies ein
11/18Lonza investiert für Moderna-Auftrag 80 bis 90 Millionen Franken in Produktio..
11/18Lonza erweitert Herstellungskapazität für Tabletten in Florida
11/18Deux vaccins contre le Covid-19 sont sûrs et efficaces à 95%
11/17MODERNA : le retard pour signer le contrat avec l'Europe va "ralentir"
11/17Lonza-Aktien setzen mit Moderna-News neues Allzeithoch
11/16Moderna, la petite société qui veut résoudre la pandémie
11/16Moderna-Impfstoff kommt von Schweizer Lonza
Analyst Recommendations on LONZA GROUP AG
2019Lonza fills portfolio hole by buying Novartis drug bottling plant
RE
2013Roche tops forecast as new cancer drugs gain momentum
RE
More recommendations
Press releases
11/19LONZA : and Be The Match BioTherapies partner to expand Vein-to-Vein Cell and Ge..
PU
11/19LONZA : Expands Highly Potent Drug Product Development and Manufacturing Capabil..
AQ
11/17MODERNA : Lonza Congratulates Moderna on Interim Phase 3 Clinical Trial Data
AQ
11/16LONZA : Congratulates Moderna on Interim Phase 3 Clinical Trial Data
PU
11/13FUJIFILM : Cellular Dynamics and Lonza Agree to Expand the Availability and Use ..
AQ
More press releases
Analysis
Moderna eyes third quarter for first doses of potential COVID-19 vaccine with Catalent deal
Stock Trading Strategies
TRADING
 The stock is approaching a major resistance level
Official Publications
08/14Half-year results 
06/30Nomination 
04/28Dividends 
04/28Proxy Statments 
03/11Nomination 
01/21Press Release 
Upcoming event on LONZA GROUP AG
01/28/21Jahr 2020 Ergebnisveröffentlichung
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Biotechnology & Medical Research - NEC
Categories
Free services
Mobile App
SOLUTIONS
About
Stock Market Quotes Interactive brokers Best of des tweets Stock Market News Börse: Aktien, Kurse und Nachrichten
Copyright © 2020 Surperformance. All rights reserved. Stock quotes are provided by Factset, Morningstar and S&P Capital IQ